EUCTR2015-003127-62-ITActive, not recruitingPhase 1
A Randomized, Placebo-Controlled, Pilot Crossover Study to Evaluate the Effect of Amifampridine Phosphate(3,4-Diaminopyridine Phosphate) in Patients with MuSK Antibody Positive Myasthenia Gravis - MuSK-001
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA0 sites20 target enrollmentStarted: March 17, 2017Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1.Willing and able to provide written informed consent after the nature of the study has been explained and before the start of any research-related procedures.
- •2.Male or female =18 years of age.
- •3.Positive serologic test for anti-MuSK antibodies as confirmed at Screening.
- •4.Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II to IV at Screening.
- •5.Myasthenia Gravis Composite (MGC) score equal or greater than 9 points is required at Screening.
- •6.Need of symptomatic treatment in order to improve muscle performance.
- •7.Patients undergoing immunosuppressive treatments may be included, but they must remain on stable treatment during the 70-day minimum study period.
- •8.Patients receiving steroids should not have any modification of drug regimen in the previous month before Screening.
- •9.Patients receiving immunosuppressive drugs (e.g. azathioprine, cyclophosphamide, methotrexate) should not have any modification of drug regimen in the previous 3 months before Screening.
- •10.Patients receiving immunomodulatory treatment (e.g. plasma exchange [PE], therapeutic plasma exchange [TPE], intravenous immunoglobulin G [IVIG]) should not have any treatment in the previous 3 weeks before Screening.
- •11.Female patients of childbearing potential must have a negative pregnancy test (serum human chorionic gonadotropin [HCG]). All patients must practice an effective, reliable and medically approved contraceptive regimen during the study and for up to 5 months following discontinuation of treatment.
- •12.Ability and availability to participate in the study for at least 70 days based on overall health of the patient and disease prognosis, as applicable, in the opinion of the investigator, and able to comply with all requirements of the protocol, including completion of study questionnaires.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 18
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
Exclusion Criteria
- •1.Hypersensitivity to the active substance, or to any of the excipients listed.
- •2.Epilepsy.
- •3.Uncontrolled asthma.
- •4.Concomitant use with sultopride.
- •5.Concomitant use with medicinal products with a narrow therapeutic window.
- •6.Concomitant use with medicinal products with a known potential to cause QTc prolongation.
- •7.Patients with congenital QT syndromes.
- •8. History of thymectomy within 12 months before Screening.
- •9.Weakness only affecting ocular or peri-ocular muscles (MGFA Class I).
- •10.MG crisis at Screening (MGFA Class V).
- •11.An electrocardiogram (ECG) within 6 months before starting treatment that shows clinically significant abnormality(ies), in the opinion of the investigator.
- •12.Breastfeeding or pregnant at Screening or planning to become pregnant (self or partner) at any time during the study. Male patients with breastfeeding partners are not excluded from the study.
- •13.Any systemic bacterial or other infection, which is clinically significant in the opinion of the investigator and has not been treated with appropriate antibiotics.
- •14.Use of PE, TPB, and/or IVIG within 3 weeks before Screening.
- •15.Use of rituximab within 6 months before Screening.
- •16.Treatment with an investigational drug (other than amifampridine), device, or biological agent within 30 days before Screening or while participating in this study.
- •17.Any medical condition that, in the opinion of the investigator, might interfere with the patient’s participation in the study, poses any added risk for the patient, or confounds the assessment of the patients.
- •18.History of drug allergy to any pyridine-containing substances or any amifampridine excipient(s).
Investigators
Similar Trials
Active, not recruiting
Phase 1
A study to explore the benefits of AUT00063 in adults receiving Cochlear ImplantEUCTR2015-003929-34-GBAutifony Therapeutics Limited15
Completed
Phase 3
Effectiveness of Homoeopathic medicines in AutismCTRI/2016/04/006856Central Council for Research in Homoeopathy79
Completed
Not Applicable
Cross-over randomized placebo-controlled pilot study to determine the effect in healthy elderly volunteers of the anti-ageing supplement *Promanna** on a number of biomarkers associated with DNA-damage and oxidative stress (PromAge)iet van toepassing, het gaat om gezonde vrijwilligers.NA (this is about healthy ageing)NL-OMON40413niversitair Medisch Centrum Groningen20
Active, not recruiting
Not Applicable
The Influence of Ivabradine on the Symptoms of Neuropathic Pain (IISNeP)europathic PainMedDRA version: 14.0Level: PTClassification code 10029223Term: NeuralgiaSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-003933-32-GBCambridge University Hospitals NHS Foundation Trust and the University of Cambridge12
Active, not recruiting
Phase 1
Clinical study evaluating the effect of Amifampridine Phosphate in Ambulatory Patients with Spinal Muscular Atrophy (SMA) Type 3.EUCTR2017-004600-22-ITCATALYST PHARMACEUTICALS INC.12